RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Common Variable Immunodeficiency: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Common variable immunodeficiency: B cells' impairment in an in vitro assay
Daniel Arroyo‐Sánchez et al., Journal of Translational Medicine (8 October 2026)
https://doi.org/10.1186/s12967-026-08821-8
- 2.
A PATHOGENIC NFKB2 VARIANT CAUSES COMBINED IMMUNODEFICIENCY WITH THYMIC AND PERIPHERAL LYMPHOID DEFECTS IN RATS
Séverine Remy et al., bioRxiv (Cold Spring Harbor Laboratory) (8 October 2026)
https://doi.org/10.64898/2026.10.02.756202
- 3.
Use of subcutaneous infliximab biosimilar CT-P13 in the Common Variable Immune Deficiency associated enteropathy.
Quera Rodrigo et al., Revista espanola de enfermedades digestivas (8 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42847868/
- 4.
Pathway-level transcriptional convergence between Gaucher disease and Common variable immunodeficiency reveals concordant interferon and antigen-processing signatures.
Bisht Akansha et al., Immunology letters (6 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42838458/
- 5.
Patient Trajectories from Electronic Health Records Suggest Specialty Specific Warning Signs for Common Variable Immunodeficiency
Rachel Mester et al., medRxiv (5 October 2026)
https://doi.org/10.64898/2026.10.01.26364525
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Common Variable Immunodeficiency
Common Variable Immunodeficiency is the most common symptomatic primary antibody deficiency, characterised by low immunoglobulin levels, poor vaccine responses, and increased susceptibility to recurrent infections. It is typically diagnosed in the second or third decade of life. Treatment requires regular immunoglobulin replacement therapy.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common variable immunodeficiency (CVID) is a primary humoral immunodeficiency of uncertain origin. Patients with CVID usually fail to respond to vaccination, but recent evidence observing partial response to mRNA vaccines suggests residual B-cell functionality. In this work, we developed a model to investigate CVID patient´s B-cell function using an in vitro stimulation model, consisting of the isolation of peripheral blood mononuclear cells (PBMCs) from 20 patients with CVID and healthy controls and cultured them with IL-2 and R848. Antibody production was assessed by ELISA and ELISPOT, cytokines were quantified in culture supernatants, and flow cytometry and transcriptomic analyses were performed to characterize cellular and molecular responses. After 10 days of culture, patients failed to sustain antibody production and showed a predominance of IgD-CD27- B cells, while antibodies remained detectable in the culture supernatants. On day 6, the proportion of memory B cells was comparable to healthy controls. The transcriptome analysis showed that patients decreased the expression of genes related to antibody production, adhesion and proinflammatory molecules but increased expression of genes associated with immune inhibitory responses. In the patient’s supernatant, APRIL and IFN-α concentrations were lower but higher BTLA concentration when compared with HC. These findings may suggest new insights into functional impairment after TLR stimulation, which may be relevant to B-cell dysfunction in patients with CVID.
Common Questions
What is Common Variable Immunodeficiency?
Common Variable Immunodeficiency is the most common symptomatic primary antibody deficiency, characterised by low immunoglobulin levels, poor vaccine responses, and increased susceptibility to recurrent infections. It is typically diagnosed in the second or third decade of life. Treatment requires regular immunoglobulin replacement therapy.
How many clinical trials are available for Common Variable Immunodeficiency?
RareWays currently indexes 35 clinical trials for Common Variable Immunodeficiency, of which 6 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Common Variable Immunodeficiency come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Common Variable Immunodeficiency.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.